Cryoport Past Earnings Performance
Past criteria checks 0/6
Cryoport's earnings have been declining at an average annual rate of -32.6%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 41.6% per year.
Key information
-32.6%
Earnings growth rate
-28.4%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 41.6% |
| Return on equity | -20.4% |
| Net Margin | -46.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk
Apr 15
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 15Cryoport Tanks On Chilling Results And Bad Decisions
Mar 14Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?
Mar 10Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)
Jan 15Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Oct 06Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term
Jul 23Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity
Jul 12Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Jun 13Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 06Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially
Nov 07Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?
Sep 23Cryoport: A Rare Investing Opportunity
Sep 22Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services
Sep 08Cryoport: Rapid Growth Is Great, But Shares Look Overpriced
Jul 30Cryoport: To Resume Aggressive Growth
May 11Cryoport: An Industry Leader Basking In Industry Tailwinds
Apr 15Cryoport: Risky Investment With Upside Potential
Apr 01Cryoport: More Growth Going Into New Year 2022
Dec 29Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?
Dec 05What Is Cryoport, Inc.'s (NASDAQ:CYRX) Share Price Doing?
Nov 09Is Cryoport (NASDAQ:CYRX) Using Too Much Debt?
Oct 17Cryoport: The Golden Stock
Oct 08Cryoport: Unfairly Punished, Valuation Update Shows 45% Upside
Oct 01Cryoport: Best Price-Positioned Medical Services Stock, As Seen By Market-Makers
Jul 01Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 47% Discount?
Jun 08Revenue & Expenses BreakdownBeta
How Cryoport makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 233 | -108 | 140 | 18 |
| 30 Sep 23 | 236 | -55 | 134 | 18 |
| 30 Jun 23 | 241 | -47 | 128 | 17 |
| 31 Mar 23 | 248 | -38 | 125 | 16 |
| 31 Dec 22 | 237 | -45 | 118 | 16 |
| 30 Sep 22 | 233 | -296 | 109 | 15 |
| 30 Jun 22 | 230 | -297 | 103 | 15 |
| 31 Mar 22 | 222 | -293 | 98 | 16 |
| 31 Dec 21 | 223 | -284 | 98 | 17 |
| 30 Sep 21 | 215 | -76 | 93 | 16 |
| 30 Jun 21 | 169 | -78 | 77 | 15 |
| 31 Mar 21 | 122 | -77 | 61 | 12 |
| 31 Dec 20 | 79 | -75 | 47 | 9 |
| 30 Sep 20 | 40 | -22 | 28 | 7 |
| 30 Jun 20 | 38 | -23 | 36 | 6 |
| 31 Mar 20 | 37 | -20 | 33 | 5 |
| 31 Dec 19 | 34 | -18 | 31 | 4 |
| 30 Sep 19 | 30 | -20 | 31 | 3 |
| 30 Jun 19 | 26 | -9 | 20 | 2 |
| 31 Mar 19 | 22 | -9 | 18 | 2 |
| 31 Dec 18 | 20 | -10 | 17 | 2 |
| 30 Sep 18 | 17 | -10 | 16 | 2 |
| 30 Jun 18 | 15 | -9 | 15 | 2 |
| 31 Mar 18 | 13 | -9 | 14 | 1 |
| 31 Dec 17 | 12 | -8 | 13 | 1 |
| 30 Sep 17 | 11 | -10 | 12 | 1 |
| 30 Jun 17 | 10 | -10 | 11 | 1 |
| 31 Mar 17 | 9 | -12 | 11 | 1 |
| 31 Dec 16 | 8 | -13 | 11 | 1 |
| 30 Sep 16 | 7 | -12 | 11 | 1 |
| 30 Jun 16 | 6 | -12 | 11 | 1 |
| 31 Mar 16 | 6 | -15 | 10 | 0 |
| 31 Dec 15 | 6 | -16 | 9 | 0 |
| 30 Sep 15 | 5 | -15 | 8 | 0 |
| 30 Jun 15 | 4 | -16 | 7 | 0 |
| 31 Mar 15 | 4 | -12 | 6 | 0 |
| 31 Dec 14 | 4 | -10 | 6 | 0 |
| 30 Sep 14 | 3 | -10 | 6 | 0 |
| 30 Jun 14 | 3 | -21 | 5 | 0 |
| 31 Mar 14 | 3 | -20 | 5 | 0 |
| 31 Dec 13 | 2 | -20 | 5 | 0 |
| 30 Sep 13 | 2 | -20 | 5 | 0 |
| 30 Jun 13 | 1 | -6 | 5 | 0 |
Quality Earnings: CYRX is currently unprofitable.
Growing Profit Margin: CYRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYRX is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.
Accelerating Growth: Unable to compare CYRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYRX is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: CYRX has a negative Return on Equity (-20.36%), as it is currently unprofitable.